Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and gsk2141795

lapatinib has been researched along with gsk2141795 in 2 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(gsk2141795)		Trials
(gsk2141795)		Recent Studies (post-2010) (gsk2141795)
1,9193051,44219819

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)gsk2141795 (IC50)
Serine/threonine-protein kinase Sgk1Homo sapiens (human)0.211
Serine/threonine-protein kinase D3Homo sapiens (human)0.753
Protein kinase C gamma typeHomo sapiens (human)0.753
Protein kinase C beta typeHomo sapiens (human)0.753
Protein kinase C alpha typeHomo sapiens (human)0.753
Ribosomal protein S6 kinase beta-1Homo sapiens (human)0.06
Protein kinase C eta typeHomo sapiens (human)0.753
RAC-alpha serine/threonine-protein kinaseHomo sapiens (human)0.0086
RAC-beta serine/threonine-protein kinaseHomo sapiens (human)0.0084
Protein kinase C iota typeHomo sapiens (human)0.753
Protein kinase C epsilon typeHomo sapiens (human)0.753
Protein kinase C theta typeHomo sapiens (human)0.753
Protein kinase C zeta typeHomo sapiens (human)0.753
Protein kinase C delta typeHomo sapiens (human)0.753
Rho-associated protein kinase 1Homo sapiens (human)0.125
Serine/threonine-protein kinase D1Homo sapiens (human)0.753
Ribosomal protein S6 kinase alpha-1Homo sapiens (human)0.339
RAC-gamma serine/threonine-protein kinaseHomo sapiens (human)0.0013

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Bayani, N; Billig, J; Collisson, EA; Cooper, B; Esch, A; Feiler, H; Gray, JW; Griffith, OL; Heiser, M; Hung, JL; Itani, S; Jakkula, L; Korkola, JE; Kuo, WL; Lu, Y; Mills, GB; Mukherjee, S; Oates, C; Spellman, PT; Thompson, W; Tomlin, C; Wang, NJ; Ziyad, S1

Other Studies

2 other study(ies) available for lapatinib and gsk2141795

ArticleYear
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Antineoplastic Agents; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Diamines; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mammary Glands, Human; Mutation; Oxadiazoles; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptor, ErbB-2; Ribosomal Protein S6; Signal Transduction

2015